公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS | Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; CHIH-HSIN YANG ; Wang J.; Babu K.G.; Nakayama Y.; Alip A.; Chua K.L.M.; CHIA-HSIEN CHENG ; Senan S.; Ahn Y.C.; Kim T.-Y.; Ahn H.K.; Peters S.; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 66 | 58 | |
2021 | Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial | Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG ; Ducreux M. | The Lancet Oncology | 159 | 141 | |
2018 | A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma | Yen C.-J.; Kim T.-Y.; Feng Y.-H.; Chao Y.; Lin D.-Y.; Ryoo B.-Y.; Huang D.C.-L.; Schnell D.; Hocke J.; Loemb? A.-B.; ANN-LII CHENG | Liver Cancer | 19 | 22 | |
2021 | Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression | Ryoo B.-Y.; ANN-LII CHENG ; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S. | British Journal of Cancer | 20 | 17 | |
2014 | Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines | Malaguarnera R.; KUEN-YUAN CHEN ; Kim T.-Y.; Dominguez J.M.; Voza F.; Ouyang B.; Vundavalli S.K.; Knauf J.A.; Fagin J.A. | Journal of Clinical Endocrinology and Metabolism | 22 | 21 |